These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 23703656)
1. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Falcinelli E; Francisci D; Belfiori B; Petito E; Guglielmini G; Malincarne L; Mezzasoma A; Sebastiano M; Conti V; Giannini S; Bonora S; Baldelli F; Gresele P Thromb Haemost; 2013 Aug; 110(2):349-57. PubMed ID: 23703656 [TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D; Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533 [TBL] [Abstract][Full Text] [Related]
3. Abacavir induces platelet-endothelium interactions by interfering with purinergic signalling: A step from inflammation to thrombosis. Alvarez A; Rios-Navarro C; Blanch-Ruiz MA; Collado-Diaz V; Andujar I; Martinez-Cuesta MA; Orden S; Esplugues JV Antiviral Res; 2017 May; 141():179-185. PubMed ID: 28263802 [TBL] [Abstract][Full Text] [Related]
4. Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. Falcinelli E; Francisci D; Schiaroli E; Minuz P; Orsini S; Malincarne L; Sebastiano M; Mezzasoma AM; Pasticci MB; Guglielmini G; Baldelli F; Gresele P Int J Cardiol; 2018 Jul; 263():118-124. PubMed ID: 29685693 [TBL] [Abstract][Full Text] [Related]
5. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. Maggi P; Montinaro V; Bellacosa C; Pietanza S; Volpe A; Graziano G; Strippoli GF; Angarano G AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504 [TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS; AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866 [TBL] [Abstract][Full Text] [Related]
7. Abacavir has no prothrombotic effect on platelets in vitro. Diallo YL; Ollivier V; Joly V; Faille D; Catalano G; Jandrot-Perrus M; Rauch A; Yeni P; Ajzenberg N J Antimicrob Chemother; 2016 Dec; 71(12):3506-3509. PubMed ID: 27516475 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk. Taylor KA; Smyth E; Rauzi F; Cerrone M; Khawaja AA; Gazzard B; Nelson M; Boffito M; Emerson M Br J Pharmacol; 2019 Apr; 176(7):879-889. PubMed ID: 30681136 [TBL] [Abstract][Full Text] [Related]
9. Short-term in vivo modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F Pastori D; Esposito A; Carnevale R; Bartimoccia S; Nocella C; Fantauzzi A; Pignatelli P; Violi F; Mezzaroma I HIV Med; 2016 Nov; 17(10):774-777. PubMed ID: 27164434 [TBL] [Abstract][Full Text] [Related]
10. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation. Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment. De Pablo C; Orden S; Calatayud S; Martí-Cabrera M; Esplugues JV; Alvarez A Antivir Ther; 2012; 17(8):1615-9. PubMed ID: 22954798 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. Leeansyah E; Cameron PU; Solomon A; Tennakoon S; Velayudham P; Gouillou M; Spelman T; Hearps A; Fairley C; Smit de V; Pierce AB; Armishaw J; Crowe SM; Cooper DA; Koelsch KK; Liu JP; Chuah J; Lewin SR J Infect Dis; 2013 Apr; 207(7):1157-65. PubMed ID: 23303810 [TBL] [Abstract][Full Text] [Related]
13. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM; AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917 [TBL] [Abstract][Full Text] [Related]
14. Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen. Tunjungputri RN; Van Der Ven AJ; Schonsberg A; Mathan TS; Koopmans P; Roest M; Fijnheer R; Groot PG; de Mast Q AIDS; 2014 Sep; 28(14):2091-6. PubMed ID: 25265076 [TBL] [Abstract][Full Text] [Related]
16. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561 [TBL] [Abstract][Full Text] [Related]
17. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977 [TBL] [Abstract][Full Text] [Related]
18. Platelet activation patterns are different in mouse models of diabetes and chronic inhibition of nitric oxide synthesis. Rozalski M; Kassassir H; Siewiera K; Klepacka A; Sychowski R; Watala C Thromb Res; 2014 Jun; 133(6):1097-104. PubMed ID: 24731558 [TBL] [Abstract][Full Text] [Related]